Russel Kinnel, director of fund research for Morningstar, has shared his list of winners for the first half of 2015. “I looked at the top and bottom performers in the Morningstar 500 by total return and ranking relative to their Morningstar Category,” Kinnel explained in a recent Morningstar commentary.
“It’s a useful exercise, because everyone wants to know why their fund is having extreme performance, and that information can help you to understand how other funds in your portfolio performed,” he explained.
Still, the fund expert cautioned: “This isn’t a buy list. That’s what our Morningstar Medalists list is for.”
For advisors and investors who’ve been following different equity sectors, especially the run-up in biotech stocks, the winners should not come as a huge surprise.
What Your Peers Are Reading
Topping the list is the T. Rowe Price Health Sciences Fund, with a total return of 20%.